Real-world safety assessment of Mpox Vaccine in Catalonia: Retrospective Cohort Study of Adverse Events of Special Interest and Breakthrough Infections

Mpox vaccination with the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine has been used to protect people at increased risk of infection, but real-world safety data from Europe remain limited. We conducted a retrospective cohort study of 8,039 adults in Catalonia, Spain, who received at least one MVA-BN dose between June 13, 2022 and December 31, 2024, using routinely collected primary care and linked hospital records. We looked for five prespecified adverse events of special interest (myocarditis, pericarditis, thrombocytopenia, anaphylaxis and generalized convulsive seizure) within 28 days after each dose, and described mpox infections diagnosed after vaccination. Participants were predominantly men (97.7%) and aged 26–45 years (68.0%). Adverse events were rare: fewer than five cases of pericarditis occurred within 28 days of vaccination (day 19 after the first dose), and no other event of special interest was identified in that window. Sixteen participants (0.20%; 95% confidence interval 0.11–0.32%) had a recorded mpox diagnosis after vaccination. These findings provide preliminary, region-specific reassurance about the short-term safety of MVA-BN. However, events were few, there was no unvaccinated comparison group, and the study cannot establish causality or vaccine effectiveness. Continued monitoring of vaccine safety is warranted.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11692999/v1
Primary Topic
Poxvirus research and outbreaks
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Real-world safety assessment of Mpox Vaccine in Catalonia: Retrospective Cohort Study of Adverse Events of Special Interest and Breakthrough Infections

Irma Convertino, Felipe Villalobos, Martín Solórzano, Aaron Switzer Rodriguez¹˒² et al.
6 links
Research Square
Poxvirus research and outbreaks
preprint

Real-world safety assessment of Mpox Vaccine in Catalonia: Retrospective Cohort Study of Adverse Events of Special Interest and Breakthrough Infections

Irma Convertino, Felipe Villalobos, Martín Solórzano, Aaron Switzer Rodriguez¹˒², Marc Far¹, Víctor Roigé-Peña¹
preprint en

Abstract

Mpox vaccination with the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine has been used to protect people at increased risk of infection, but real-world safety data from Europe remain limited. We conducted a retrospective cohort study of 8,039 adults in Catalonia, Spain, who received at least one MVA-BN dose between June 13, 2022 and December 31, 2024, using routinely collected primary care and linked hospital records. We looked for five prespecified adverse events of special interest (myocarditis, pericarditis, thrombocytopenia, anaphylaxis and generalized convulsive seizure) within 28 days after each dose, and described mpox infections diagnosed after vaccination. Participants were predominantly men (97.7%) and aged 26–45 years (68.0%). Adverse events were rare: fewer than five cases of pericarditis occurred within 28 days of vaccination (day 19 after the first dose), and no other event of special interest was identified in that window. Sixteen participants (0.20%; 95% confidence interval 0.11–0.32%) had a recorded mpox diagnosis after vaccination. These findings provide preliminary, region-specific reassurance about the short-term safety of MVA-BN. However, events were few, there was no unvaccinated comparison group, and the study cannot establish causality or vaccine effectiveness. Continued monitoring of vaccine safety is warranted.

Research Square
University of Pisa (IT), Universitat Pompeu Fabra (ES), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
Good health and well-being
Poxvirus research and outbreaks
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Real-world safety assessment of Mpox Vaccine in Catalonia: Retrospective Cohort Study of Adverse Events of Special Interest and Breakthrough Infections — Irma Convertino, Felipe Villalobos, et al. · Research Square (2026) | TGRS Research Map | TGRS